Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Adarx Pharmaceuticals Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners across 3 distinct art units, so each file has a separate examiner assignment while some technical grouping remains.
HUDSON, AMY ROSE is the busiest examiner, with 1 pending matter. No examiner carries more than that listed figure, making individual response planning and consistent deadline control the principal prosecution needs.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697180 | PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | BRETZ, COREY LANE | — |
| 18286640 | RNA SILENCING AGENTS AND METHODS OF USE | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19630043 | ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | — |
| 18697165 | ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | VANHORN, ABIGAIL LOUISE | — |
| 18286640 | RNA SILENCING AGENTS AND METHODS OF USE | POLIAKOVA-GEORGAN, EKATERINA | — |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1635 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19630043 | ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | HUDSON, AMY ROSE | 1636 | §103 | Final Rejection | — | Pending | Mar 26, 2026 |
| 18697180 | PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | BRETZ, COREY LANE | 1635 | §112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18697165 | ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | VANHORN, ABIGAIL LOUISE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18286640 | RNA SILENCING AGENTS AND METHODS OF USE | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdarx Pharmaceuticals Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Amy Rose Hudson has the most, with 1 of Adarx Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
